Current Report Filing (8-k)
September 04 2018 - 4:58PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 4, 2018
MICROBOT
MEDICAL INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-19871
|
|
94-3078125
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
25
Recreation Park Drive, Unit 108
Hingham,
Massachusetts 02043
|
(Address
of Principal Executive Offices) (Zip Code)
|
Registrant’s
telephone number, including area code: (781) 875-3605
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
I
tem
3.03
|
Material
Modification to Rights of Security Holders.
|
To
the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated
herein by reference.
Item
5.03
|
Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
On
September 4, 2018, as approved by the stockholders of Microbot Medical Inc. (the “Company”) at the annual meeting
of the Company’s stockholders held on September 4, 2018 (the “Annual Meeting”), the Company filed a Certificate
of Amendment to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a one-for-15
reverse stock split of the Company’s common stock (the “Certificate of Amendment”). As a result of the reverse
stock split, every 15 shares of the Company’s old common stock will be converted into one share of the Company’s new
common stock. Fractional shares resulting from the reverse stock split will be rounded up to the nearest whole number.
The
foregoing description of the Certificate of Amendment is not complete and is subject to, and qualified in its entirety by, the
full text of the Certificate of Amendment, which is attached to this Current Report on Form 8-K as Exhibit 3.1, the terms of which
are incorporated herein by reference.
Item
5.07
|
Submission
of Matters to a Vote of Security Holders
|
At
the Annual Meeting, the stockholders voted on the following three proposals and cast their votes as described below. The proposals
are described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities
and Exchange Commission on July 27, 2018 (the “Proxy Statement”).
Proposal
1:
|
Election
of the two nominees listed below to serve as Class III Directors on the Board of Directors of the Company until the 2021 Annual
Meeting of Shareholders and until their respective successors have been duly elected and qualified:
|
Name
|
|
Number of Votes
Cast in Favor
|
|
Number of Votes
Cast Against
|
|
Number of Votes
Abstained
|
Yoseph Bornstein
|
|
19,115,974
|
|
459,954
|
|
84,863
|
Prattipati Laxminarain
|
|
19,124,930
|
|
438,783
|
|
97,078
|
Proposal
2:
|
The
ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as
the Company’s independent registered public accounting firm for the year ending December 31, 2018:
|
Number of Votes
Cast in Favor
|
|
Number of Votes
Cast Against
|
|
Number of Votes
Abstained
|
34,949,937
|
|
1,161,116
|
|
371,808
|
Proposal
3.
|
The
approval of an amendment to the Company’s certificate of incorporation to effect a reverse stock split of not less than
one-for-five (1:5) and not greater than one-for-twenty (1:20), of the common stock of the Company:
|
Number of Votes
Cast in Favor
|
|
Number of Votes
Cast Against
|
|
Number of Votes
Abstained
|
27,217,446
|
|
9,155,946
|
|
109,469
|
Item
7.01
|
Regulation
FD Disclosure.
|
On
September 5, 2018, Harel Gadot, Chief Executive Officer, President and Chairman of the Company, is scheduled to present at 1:45
P.M. (ET) at the Rodman & Renshaw 20th Annual Global Investment Conference, sponsored by H.C. Wainwright, at the St. Regis
Hotel in New York City. A live webcast and subsequent archived replay of the Company’s presentation may be accessed via
the ‘Investors’ section, under ‘Presentations and Resources’ of the Company’s website at www.microbotmedical.com.
The Company is furnishing presentation materials included as Exhibit 99.1 to this Current Report on Form 8-K. The Company is not
undertaking to update this presentation.
The
information in this Item 7.01 and in Exhibit 99.1 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed
to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this
Item 7.01 or Exhibit 99.1 of Item 9.01.
Item
9.01
|
Financial
Statements and Exhibits.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
MICROBOT
MEDICAL INC.
|
|
|
|
By:
|
/s/
Harel Gadot
|
|
Name:
|
Harel
Gadot
|
|
Title:
|
President,
Chief Executive Officer and Chairman
|
|
|
|
Date:
September 4, 2018
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Microbot Medical (NASDAQ:MBOT)
Historical Stock Chart
From Sep 2023 to Sep 2024